8-K: ARS Pharmaceuticals Receives FDA Approval for Neffy 1 mg Nasal Spray for Pediatric Allergic Reactions

ARS Pharmaceuticals announces FDA approval of Neffy 1 mg nasal spray for emergency treatment of allergic reactions in children aged four and older weighing 15 to under 30 kilograms.

Summary

• ARS Pharmaceuticals announced that the FDA approved Neffy 1 mg (epinephrine nasal spray) on March 5, 2025.
• Neffy 1 mg is approved for the emergency treatment of allergic reactions, including anaphylaxis, in children aged four years and older weighing 15 to under 30 kilograms (33lbs to under 66 lbs).
• The approval is based on data from clinical trials showing pharmacokinetic and pharmacodynamic responses consistent with epinephrine injection products.
• Adverse events in pediatric trials were generally mild and transient.
• Human factor studies showed that children as young as ten and untrained individuals can effectively administer Neffy 1 mg.
• Neffy 1 mg is expected to be available in the U.S. by the end of May 2025.
• The FDA previously approved Neffy 2 mg on August 9, 2024, for children and adults weighing 30kg (66 lbs.) and over.
• The European Commission approved EUR Neffy on August 22, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA approval of Neffy 1 mg, which is a significant milestone for ARS Pharmaceuticals. The approval expands the company's product offerings and addresses a specific need in the pediatric population. However, the presence of forward-looking statements and associated risks tempers the overall sentiment.

Positives

• FDA approval of Neffy 1 mg provides a new treatment option for allergic reactions in young children.
• Clinical trial data supports the efficacy and safety of Neffy 1 mg.
• Human factor studies indicate ease of use for both children and untrained individuals.
• The product is expected to be available in the U.S. by the end of May 2025.

Risks

• The company's ability to maintain regulatory approval for Neffy is a risk.
• Complications associated with supply and distribution could impact the availability of Neffy.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates Neffy 1 mg will be available in the U.S. by the end of May 2025, but this timeline is subject to risks and uncertainties.

Management Comments

• Richard Lowenthal, M.S., MBA, President and Chief Executive Officer, signed the report on behalf of ARS Pharmaceuticals, Inc.

Industry Context

This approval positions ARS Pharmaceuticals to compete in the epinephrine delivery market, offering a needle-free alternative for treating allergic reactions in young children. It expands their product line following the approval of Neffy 2 mg for older children and adults.

Comparison to Industry Standards

• The approval of Neffy 1 mg provides an alternative to existing epinephrine injection products like EpiPen and Auvi-Q, offering a needle-free nasal spray option.
• The clinical trial data for Neffy 1 mg is being compared to the pharmacokinetic and pharmacodynamic responses of existing epinephrine injection products.
• The human factor studies are being compared to the ease of use and administration of existing epinephrine auto-injectors.

Stakeholder Impact

• Shareholders will likely react positively to the FDA approval.
• Patients and caregivers will have a new treatment option for allergic reactions in young children.
• The company's employees may experience increased workload related to the commercial launch of Neffy 1 mg.

Next Steps

• ARS Pharmaceuticals will focus on the commercial launch of Neffy 1 mg in the U.S., expected by the end of May 2025.
• The company will continue to monitor and maintain regulatory approval for Neffy.

Key Dates